Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Thamir M Alshammari1 Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia;2 Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia;3 Saudi Food and Drug Authority, Riyadh, Saudi ArabiaCorrespondence[email protected]

Sondus I Ata4 Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia

Mansour Adam Mahmoud5 Department of Clinical Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia

Tariq M Alhawassi2 Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia;4 Pharmacy Services, King Saud University Medical City, Riyadh, Saudi Arabia;6 Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Hisham S Aljadhey3 Saudi Food and Drug Authority, Riyadh, Saudi Arabia

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Abdulrhman Alrowily, Zahraa Jalal, Mohammed H. Abutaleb, Nermin A. Osman, Maha Alammari & Vibhu Paudyal. (2021) Medication errors associated with direct-acting oral anticoagulants: analysis of data from national pharmacovigilance and local incidents reporting databases. Journal of Pharmaceutical Policy and Practice 14:1.
Read now

Articles from other publishers (5)

Dandan Li, Cilin Yan, Mingxing Guo, Ying Zhao, Yang Zhang & Xiangli Cui. (2023) Evidence of potential pro‐haemorrhagic drug interactions between CYP3A4 inhibitors and direct oral anticoagulants: Analysis of the FAERS database. British Journal of Clinical Pharmacology.
Crossref

Mingxing Guo, Sydney Thai, Junwen Zhou, Jingkai Wei, Ying Zhao, Wanyi Xu, Tiansheng Wang & Xiangli Cui. (2021) Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database. International Journal of Clinical Pharmacy 43:6, pages 1508-1515.
Crossref

Ghanshyam Mali, Vivek Ahuja & Kiran Dubey. (2020) Glucagon‐like peptide‐1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database. Journal of Clinical Pharmacy and Therapeutics 46:1, pages 99-105.
Crossref

Mina T. Kelleni. 2020. Anticoagulation Drugs - the Current State of the Art. Anticoagulation Drugs - the Current State of the Art.

Emma P. DeLoughery & Joseph J. Shatzel. (2019) A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system. European Journal of Haematology 103:1, pages 43-46.
Crossref

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

Citations (6)

Read on this site (1)

Articles from other publishers (5)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date